Page values for "Buprenorphine/Naloxone"
From Pharmacopedia
More actions
"Medicines" values
1 row is stored for this page| Field | Field type | Value |
|---|---|---|
| generic | String | Buprenorphine / Naloxone |
| brand | String | Suboxone, Zubsolv, Bunavail, Cassipa |
| structure | File | |
| classes | List of String, delimiter: , | Opioid agonist therapy (OAT); Partial μ-agonist + abuse-deterrent |
| mechanism | String | Buprenorphine: high-affinity partial agonist at the μ-opioid receptor with ceiling effect on respiratory depression. Naloxone: abuse-deterrent, inactive SL but precipitates withdrawal if injected. |
| uses | String | '"`UNIQ--vote-00000095-QINU`"', '"`UNIQ--vote-00000096-QINU`"' |
| starting_dose | String | Induction: 2/0.5 to 4/1 mg SL once in moderate withdrawal; titrate to 12–16/3–4 mg/d by day 2–3 |
| preparations | String | SL film or tablet, 2/0.5 to 12/3 mg per dose |
| fda_max | String | 24/6 mg/d (most labels) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Sublingual film or tablet (buccal for some) |
| onset | String | 30–60 min (SL) |
| duration | String | 24–36 h (driven by buprenorphine) |
| halflife | String | 24–42 h (buprenorphine); 1–2 h (naloxone) |
| bioavailability | String | Buprenorphine ~30% SL; naloxone <10% SL (intentional, inactive sublingually, matters only if injected) |
| pregnancy | String | Category C (buprenorphine-only formulations preferred in pregnancy) |
| legal | String | Schedule III in US; X-waiver no longer required (as of 2023) |